NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
08 October 2024
| Name: | SUDA PHARMACEUTICALS LTD (SUD) (This company subsequently changed its name to AROVELLA THERAPEUTICS LIMITED. You should refer to that name for Status.) | |||||||||
| ISIN: | AU000000SUD7 | |||||||||
| Date of Listing: | 24 January 2002 | |||||||||
| Subsequent Names: |
| |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to AROVELLA THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
ACN: 090 987 250ABN: 35 090 987 250
Registration Date: 21 December 1999
Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now AROVELLA THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| AROVELLA THERAPEUTICS LIMITED | 25/10/2021 | |
| SUDA PHARMACEUTICALS LTD | 05/12/2017 | 25/10/2021 |
| SUDA LTD | 07/12/2012 | 05/12/2017 |
| EASTLAND MEDICAL SYSTEMS LTD | 07/12/2012 |
Advanced Share Registry Services
110 Stirling Hwy, Nedlands WA 6009
Tel : +61 8 9389 8033
Fax : +61 8 9262 3723
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to Arovella Therapeutics Limited | 25/10/2021 |
The suspension of trading in the securities of SUDA Pharmaceuticals Ltd will be lifted immediately following the release by SUD of an announcement regarding a market update. | 25/06/2020 |
In the lead up to the company requesting a trading halt, Suda had established an independent transaction committee to assess and pursue the material licensing transaction, conducted extensive due diligence inquiries on, and an independent valuation of, the target asset, advanced negotiations of the transaction documents. ASX has now formally advised the company that there is a significant likelihood the ASX will exercise its discretion to decline Suda's application for readmission if it chooses to proceed with the proposed transaction. With ASX's current determination, it is not possible for the company to proceed with the proposed transaction. The accompanying capital raising will, accordingly, also not proceed at this time. | 25/06/2020 |
The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement regarding a proposed licensing transaction and a capital raising. | 05/06/2020 |
we understand that on or about this date the company consolidated its shares 1 for 25 | 22/11/2019 |
The suspension of trading in the securities of Suda Pharmaceuticals Ltd will be lifted immediately, following receipt of a response to an ASX Query. | 17/10/2018 |
The company issues a response to ASX query. | 17/10/2018 |
The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.3. | 17/10/2018 |
name changed from Suda Ltd | 05/12/2017 |
name changed to Arovella Therapeutics Limited | 25/10/2021 |
The suspension of trading in the securities of SUDA Pharmaceuticals Ltd will be lifted immediately following the release by SUD of an announcement regarding a market update. | 25/06/2020 |
In the lead up to the company requesting a trading halt, Suda had established an independent transaction committee to assess and pursue the material licensing transaction, conducted extensive due diligence inquiries on, and an independent valuation of, the target asset, advanced negotiations of the transaction documents. ASX has now formally advised the company that there is a significant likelihood the ASX will exercise its discretion to decline Suda's application for readmission if it chooses to proceed with the proposed transaction. With ASX's current determination, it is not possible for the company to proceed with the proposed transaction. The accompanying capital raising will, accordingly, also not proceed at this time. | 25/06/2020 |
The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement regarding a proposed licensing transaction and a capital raising. | 05/06/2020 |
we understand that on or about this date the company consolidated its shares 1 for 25 | 22/11/2019 |
The suspension of trading in the securities of Suda Pharmaceuticals Ltd will be lifted immediately, following receipt of a response to an ASX Query. | 17/10/2018 |
The company issues a response to ASX query. | 17/10/2018 |
The securities of Suda Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.3. | 17/10/2018 |
name changed from Suda Ltd | 05/12/2017 |
Your browser may reflect a date of printing in American format.
| Dear investogain.com.au webmaster, Good to see your posts! | 12/03/2023 21:27:42 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 10/11/2020 | Paul Hopper | 234,669 | $0.039 | $9,152 |
| 05/11/2020 | David Simmonds | 250,000 | $0.040 | $10,000 |
| 27/10/2020 | Michael Baker | 400,000 | $0.042 | $16,800 |
| 21/11/2019 | Paul Hopper | 200,000 | $0.062 | $12,310 |
| 10/09/2019 | Paul Hopper | 1,000,000 | $0.004 | $4,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Paul Hopper | Non Exec Chairman | 15/05/2019 |
| Joseph Ohayon | CFO | 01/07/2010 |
| David Simmonds | Non Exec Director | 27/03/2019 |
| Michael Baker | Executive Director, CEO | 02/01/2020 |
| David Phillips | Executive Director | 06/04/2018 |
| Phillip Hains | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Stephen Carter | Managing Director, CEO | 26/10/2010 | 23/09/2019 |
| Michael Stewart | Non Exec Chairman | 11/06/2009 | 10/04/2018 |
| Ken Robson | Non Exec Director | 08/03/2013 | 07/08/2014 |
| Peter Jooste | Non Exec Chairman | 03/07/2006 | 30/11/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
